This article was originally published in The Tan Sheet
Effective television advertising drove a 51% increase in spoon-delivered multi-symptom cold and flu relief SKU products sales during the 2007 first quarter, the Phoenix-based Zicam manufacturer reports in a May 30 regulatory filing. The firm reports its Zicam Nasal Moisturizer product was dropped from the allergy and sinus line after it failed to gain widespread distribution in 2006, however the company plans to ramp up offerings in that category with Zicam Sinus Rapid Melt with vapor action set to launch in the second half of 2007. Quarterly net sales hit $19 mil., a 7.7% increase from a year ago, the firm says. Other results include: cold remedy product sales were up 0.4% to $11.5 mil., allergy, sinus and nasal comfort sales climbed 16.1% to $4.6 mil., cough product sales increased 8% to $1.1 mil. and multi-symptom cold and flu relief sales rose 50.9% to $1.8 mil...
You may also be interested in...
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
New medicines under evaluation at the European Medicines Agency.